Proprietary, highly efficient and scalable linDNA (linear DNA, the product of PCR) manufacturing process for use in nucleic acid-based therapies. Learn how LineaRx is the common denominator of next-generation therapies.
Powering nucleic acid-based therapies into the future with LinearDNATM—The global demand for DNA continues to rise at a breakneck pace. This trend began with the introduction of redirected cell and gene therapies and was supercharged by the success of mRNA COVID-19 vaccines.
DNA-based vaccines represent a simple, safe and promising strategy for harnessing the immune system to fight infectious diseases as well as various forms of cancer.